The volume of transcatheter aortic valve replacement (TAVR) procedures performed by hospitals around the world is gradually recovering to its pre-pandemic level, according to market leader Edwards Lifesciences Corp.
In the second quarter of 2020, revenue from SAPIEN devices declined 11.5% year-over-year to $594.3m. Sales of TAVR devices were...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?